Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | PARP1 | P09874 | 6/20 | 0.64 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10134607 | 0.84 | PARP1 (0.63) | ACHEPARP1CHUKCSNK2A1MAPT | |
| SCHEMBL10134606 | 0.81 | PARP1 (0.79) | ACHEPARP1CHUKCSNK2A1MAPT | |
| SCHEMBL2151265 | 0.81 | PGR (0.68) | ACHEPARP1PGRKIF11KDM4E | |
| SCHEMBL1478179 | 0.78 | PARP1 (1.00) | ACHEPARP1CHUKCSNK2A1CDK5 | |
| SCHEMBL30704720 | 0.78 | PARP1 (1.00) | ACHEPARP1CHUKCSNK2A1CDK5 | |
| SCHEMBL9043755 | 0.72 | PARP1 (0.81) | ACHEPARP1CHUKCSNK2A1KDM4E | |
| SCHEMBL3453800 | 0.72 | AURKA (0.68) | PARP1PGRMAPTMAPK14GSK3A | |
| SCHEMBL2150990 | 0.71 | PARP1 (0.64) | PARP1PGRKDM4E | |
| SCHEMBL29548318 | 0.71 | ACHE (0.63) | ACHEPARP1CHUKMAPTKIF11 | |
| SCHEMBL27097906 | 0.71 | ACHE (0.63) | ACHEPARP1CHUKMAPTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005105814-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | ACHE 4858/4885PARP1 1861/4885CHUK 36/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | ACHE 4858/4885PARP1 1861/4885CHUK 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.